514
Participants
Start Date
February 17, 2023
Primary Completion Date
October 25, 2024
Study Completion Date
August 4, 2028
DOR/ISL
DOR/ISL 100 mg/0.25 mg oral tablets once daily
BIC/FTC/TAF
BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Placebo to BIC/FTC/TAF
0 mg oral tablets once daily
Placebo to DOR/ISL
0 mg oral tablets once daily
Holdsworth House Medical Practice ( Site 6200), Darlinghurst
St Vincent's Hospital-IBAC ( Site 6203), Sydney
Prahran Market Clinic ( Site 6202), Melbourne
Holdsworth House Medical Practice - Brisbane ( Site 6201), Brisbane
Royal Brisbane and Women's Hospital-Infectious Diseases Research ( Site 6204), Brisbane
Hadassah Medical Center-Infecious Disease ( Site 4802), Jerusalem
Whitman-Walker Institute ( Site 1431), Washington D.C.
Regional Center for Infectious Disease Research ( Site 1435), Greensboro
Infectious Disease Specialists of Atlanta ( Site 1403), Decatur
Mercer University, Department of Internal Medicine ( Site 1411), Macon
Orlando Immunology Center ( Site 1407), Orlando
AHF The Kinder Medical Group ( Site 1426), Miami
Therafirst Medical Center ( Site 1402), Fort Lauderdale
Triple O Research Institute, P.A ( Site 1417), West Palm Beach
Midway Immunology and Research Center ( Site 1401), Ft. Pierce
Be Well Medical Center ( Site 1408), Berkley
KC CARE Health Center-Clinical Trials ( Site 1422), Kansas City
Sourasky Medical Center ( Site 4804), Tel Aviv
Prism Health North Texas, Oak Cliff Health Center ( Site 1409), Dallas
North Texas Infectious Diseases Consultants, P.A ( Site 1404), Dallas
DCOL Center for Clinical Research ( Site 1415), Longview
Texas Centers for Infectious Disease Associates ( Site 1406), Fort Worth
The Crofoot Research Center ( Site 1424), Houston
St Hope Foundation ( Site 1410), Bellaire
Central Texas Clinical Research ( Site 1413), Austin
Pueblo Family Physicians ( Site 1425), Phoenix
Las Vegas Research Center ( Site 1436), Las Vegas
Ruane Clinical Research Group, Inc ( Site 1414), Los Angeles
Mills Clinical Research ( Site 1433), Los Angeles
Pacific Oaks Medical Group ( Site 1400), Beverly Hills
Rambam Health Care Campus-Institute of Allergy, Clinical Immunology, ( Site 4801), Haifa
Clinica Universidad Catolica del Maule ( Site 2204), Talca
Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 2205), Temuco
Sheba Medical Center-HIV unit ( Site 4803), Ramat Gan
Clínica Universidad de Los Andes ( Site 2206), Santiago
Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 2200), Santiago
AccessHealth MA ( Site 1419), Boston
National Hospital Organization Nagoya Medical Center ( Site 6603), Nagoya
Center Hospital of the National Center for Global Health and Medicine ( Site 6601), Shinjyuku-ku
National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 66, Osaka
Southmead Hospital ( Site 5805), Bristol
Queen Elizabeth Hospital Birmingham ( Site 5809), Birmingham
Royal Liverpool University Hospital ( Site 5812), Liverpool
Royal London Hospital ( Site 5800), London
Royal Free Hospital ( Site 5801), London
Guy's & St Thomas' NHS Foundation Trust ( Site 5808), London
The Mortimer Market Centre for Sexual Health and HIV Research ( Site 5810), London
University Hospital of Wales ( Site 5803), Cardiff
Royal Berkshire Hospital ( Site 5813), Reading
Merck Sharp & Dohme LLC
INDUSTRY